

Hepatitis B Surface Antigen Detection, Qualitative Versus Quantitative: A comparative study

Thesis

Submitted for the Partial Fulfillment of Master Degree in
Clinical and Chemical Pathology

By

Noha Mohammed Ali

MB BCh.

Faculty of Medicine, Cairo University

Supervised by

Prof./ Aisha Yassin Abdel Ghaffar

Professor of Clinical and Chemical Pathology

Faculty of Medicine, Ain Shams University

Prof./Yasser Ahmed Zeitoun

Professor of Clinical and Chemical Pathology

Faculty of Medicine, Ain Shams University

Prof./ Afaf Abd El alim Mostafa

Professor of Clinical and Chemical Pathology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2013



وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ تَكُنْ
تَعْلَمُ وَكَانَ فَضْلُ اللَّهِ
عَلَيْكَ عَظِيمًا

صدق الله العظيم

سورة
النساء الآية (113)



Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Merciful, Who gives me power to accomplish this work.*

*I would like to express my deepest appreciation and sincere gratitude to **Prof./ Aisha Yassin Abdel Ghaffar**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her sincere help, constant encouragement, constructive criticism, and valuable guidance, I was truly honoured to work under her supervision.*

*I wish also to express my great gratitude and utmost appreciation to **Prof./ Yasser Ahmed Zeitoun**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for his valuable suggestions and instructions during the progress of this work.*

*I feel deeply indebted to **Prof./ Afaf Abd El alim Mostafa**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her active cooperation, deep concern, enthusiastic encouragement, the effort and time he has devoted to the fulfillment of this work.*

Noha Mohammed Ali



*I would like to dedicate this thesis to
allmembers inMy**Family**, specially,
Mother and Father for supporting me
and pushing me forward all the time.*

*Special dedication to my**Husband**for
dealing tactfully and patiently during this
work.*



List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	v
List of Figures	vi
Introduction	1
Aim of the Work	3
Review of Literature	
Hepatitis B Virus Infection	4
Quantitative Immunoassay	86
Subjects and Methods	109
Results	118
Discussion	126
Summary	133
Conclusion and Recommendation	136
References	137
Arabic Summary	—

List of Abbreviations

Abbrev.	Full term
ADV	Adefovir
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
Anti-HBc	Antibody to hepatitis B core antigen
Anti-HBs	Antibody to hepatitis B surface antigen
anti-HBx	Anti hepatitis B x
APC	Antigen presenting cell
AST	Asprtate Transaminase
BCR	B cell receptor
BDL	Below detection limit
BL	Borderline
BSA	Bovin serum albumin
cccDNA	Covalently closed circular DNA
CD	Cluster of Differentiation
CDC	Centers of disease control and prevention
CEDIA	Cloned enzyme donor immunoassay
CHB	Chronic hepatitis b
CMIA	Chemilumescient microparticle immunoassay
CTL	Cytotoxic T lymphocyte
DC	Dendritic cell
DNA	Deoxyribonucleic acid
DR	Direct repeats
ECLIA	Electrochemiluminescence
EIA	Enzyme immunoassay
ELISA	Enzyme linked immunosorbent assay
EMIT	Enzyme multiplied immunoassay technique
ER	Endoplasmic reticulum
ETV	Entecavir

List of Abbreviations *(Cont...)*

FasL	Fas Ligand
FIA	Florescent immunoassay
FPIA	Fluorescence polarization immunoassay
GGT	Gamma-glutamyltransferase
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HAS	The French National Authority for Health
HBcAg	Hepatitis B core antigen
HBeAg	Hepatitis B envelope antigen
HBIG	Hepatitis B immunoglobulin
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HBx	Hepatitis B virus x protein
HCC	Hepatocellular carcinoma
HCG	Human chorionic gonadotropin
HCV	Hepatitis C virus
HDV	Hepatitis delta virus
HIG	Human immunoglobulin G
HIV	Human immune deficiency virus
HRP	Horseradish peroxidase
HS	Highly significant
HSPGs	Heparan sulphate proteoglycanes
I125	125 Iodine
IC	Immune clearance
ICU	Intensive care unit
IFN	Interferon
IFN-α/β	Interferon alpha/beta
IFN-γ	Interferon gamma
Ig	Immunoglobulin
IgG antibodies	Immunoglobulin G antibody
IgM Anti-HBc	Immunoglobulin M Antibody to hepatitis B core
IgMHBcAb	Immunoglobulin M hepatitis B core antibody

List of Abbreviations *(Cont...)*

IHL	Intra-hepatic lymphocytes
IL	Interleukin
INF	Interferon
IQR	Interquartile range
IRF	Interferon regulatory factor
IRMA	Immunoradiometric assay
IT	Immune-tolerant carrier
LAM	Lamivudine
LC	Low replicative phase
Ldt	Telbivudine
LHB	Large hepatitis B proteins
LN	Lymph node
MDA5	Melanoma differentiation associated gene 5
mDC	Myeloid dendritic cell
MEIA	Microparticle Enzyme Immunoassay
MHB	Middle hepatitis B proteins
MHC	Major histocompatibility complex
MIA	Magnetic immunoassay
MIP	Macrophages inflammatory protein
mRNA	messenger Ribonucleic acid
NAT	Nucleic acid testing
NC	Negative control value
NF- $\kappa\beta$	Nuclear factor- $\kappa\beta$
NK	Natural killer cell
NKT	Natural killer T cell
NR	Nonreactive
NS	Non significant
OD	Optical densities
ORF	Open reading frame
PCR	Polymerase chain reaction

List of Abbreviations *(Cont...)*

PD-1	Programmed death-1
PDL1	Programmed death ligand-1
PEI	Paul Ehrlich Institute
PEG-IFN	Pegylated interferon
PRR	Pattern recognition receptor
qHBsAg	Quantitative hepatitis B surface antigen
RIG-I	Retinoic acid-inducible gene I
QT	Quantitative technique
RFLP	Restriction fragment length polymorphism
RIA	Radioimmunoassay
RLU	Relative light unit
RNaseH	Ribonuclease
RT	Reverse transcriptase
S	Significant
SD	Standard deviation
SHB	Small hepatitis B proteins
SPSS	Statistical package for social science
SVR	Sustained virologic response
T4	Thyroxin
TCR	T cell receptor
TH	T helper
TLRs	Toll-like receptors
TNF	Tumor necrosis factor
Total Anti-HBc	Total hepatitis B core antibody
TP	Terminal protein
TRAIL	TNF-related apoptosis-inducing ligand
WHO	World health organization

List of Tables

Table No.	Title	Page No.
Table (1):	Prevalence of HBsAg, HBsAb and frequency of Neonatal, Childhood infection Worldwide	6
Table (2):	Stages of chronic HBV infection	49
Table (3):	Interpretation of serologic test results for hepatitis B.....	60
Table (4):	Discordant or unusual hepatitis B serological profiles requiring further evaluation.....	66
Table (5):	Advantages and disadvantages of HBV DNA testing	68
Table (6):	Hepatitis B tests and their uses.....	71
Table (7):	The conversion of Fibro Test into stages.....	77
Table (8):	Conversion of acti test into stages	79
Table (9):	Demographic characteristics of the studied patients	118
Table (10):	Liver Function Test Results among studied patients	120
Table (11):	Viral load among studied patients	120
Table (12):	HBsAg Results by different Methods among studied patients	121
Table (13):	Statistical correlation studies among the three methods applied for HBsAg determination among positive samples	122
Table (14):	Statistical correlation studies between HBsAg results done by three methods applied and each of AST,ALT and HBV DNA	123

List of Figures

Figure No.	Title	Page No.
Fig. (1):	Geographic distribution of chronic hepatitis B infection.....	5
Fig. (2):	A simplified drawing and electron micrograph of the HBV particle and surface antigen.....	8
Fig. (3):	Representation of hepatitis B virus (HBV) genome	9
Fig. (4):	Domains of HBV surface proteins.....	10
Fig. (5 a):	First the virus attaches to a liver cells membrane	11
Fig. (6):	The core particle releases its contents of DNA and DNA polymerase into the liver cell nucleus.....	12
Fig. (7):	Transcription.....	13
Fig. (8 a):	Assemble of 'live' copies of the virus.....	14
Fig. (9):	The Replication cycle of HBV	16
Fig. (10):	Viral assembly and release http://www. hon. ch/Library/Theme/HepB/virology. html).	16
Fig. (11):	Coordinate Activation of Innate and Adaptive Response is Necessary for HBV Control	27
Fig. (12):	The cytokine/chemokine cascade through which NK cells recruit T cells.....	30
Fig. (13):	Immunoregulatory functions of hepatic natural killer T (NKT) cells (Tan et al., 2008).....	33
Fig. (14):	DCs are the most potent APCs (Zhang et al., 2006).	36
Fig. (15):	Platelets Facilitate the Accumulation of CTLs in the Infected Liver (Iannacone et al., 2007).	38

List of Figures

Figure No.	Title	Page No.
Fig. (16):	Cellular immune responses to HBV.....	40
Fig. (17):	Correlation of T-cell Defects with Virus Replication Levels. Chronic infection/ animal model.....	41
Fig. (18):	HBV-specific T-cell Tolerance	43
Fig. (19):	Schematic Figure of How the B7-H1/PD-1 Pathway May Mediate the Exhaustion of Virus- specific T Cells in Chronic HBV Infection	46
Fig. (20):	Hepatitis B surface antigen.....	56
Fig. (21):	Antibody to HBsAg.....	57
Fig. (22):	Hepatitis B core antibody	58
Fig. (23):	Acute Hepatitis B Virus Infection With Recovery Typical Serologic Course	61
Fig. (24):	Progression to Chronic Hepatitis B Virus Infection Typical Serologic Course	64
Fig. (25):	HBV DNA	67
Fig. (26):	Interpretation of fibro test results.....	77
Fig. (27):	Interpretation of acti test results.....	78
Fig. (28):	Competitive, homogeneous immunoassay.	98
Fig. (29):	Two-site, noncompetitive immunoassays.....	100
Fig. (30):	Gender distribution among the studied patients.....	119
Fig. (31):	Receiver operating charachterstic curve analysis	124
Fig. (32):	Receiver operating charachterstic curve analysis showing the diagnostic performance of HBsAg for Elisa and Architect.....	125

Introduction

Hepatitis B virus (HBV) infection is a major global health problem. It is one of the leading causes of both liver cirrhosis and hepatocellular carcinoma, and is responsible for more than 500,000 deaths per year (*Sorrell et al., 2009*).

Chronic HBV carriers are the main source of HBV infection in the population. Thus, the detection of HBV infection in pregnant women and blood donors is required to prevent spread of the infection (*Lee et al., 1998*).

Hepatitis B surface antigen (HBsAg) is a major envelope protein of HBV, and can serve as an epitope and provide the host with immunity(*Hsu et al., 1997*).

HBsAg is one of the first serum markers to appear during the course of HBV infection and can be detected 2 to 8 weeks before biochemical evidence of liver dysfunction and the onset of jaundice. HBsAg is cleared within a few months in self-limiting illness. If HBsAg persists for more than 6 months, spontaneous clearance is very improbable and the infected individual is considered a chronic HBV carrier(*Weber et al., 1993*).

Among the many commercially licensed HBsAg assays available, enzyme-linked immunosorbent assays (ELISA) are currently the most frequently used. These assays use either monoclonal or polyclonal anti-HBs bound to a solid phase and a second labelled anti-HBs to detect the captured antigen. Despite

the high-level performance of screening assays, transfusion-associated HBV infection is still reported. To reduce the residual risk of transfusion-associated hepatitis B, the sensitivity of HBsAg screening assays is continuously improved (*Hoofnagle, 1990*).

Antiviral agents such as lamivudine and interferon- α (IFN- α) have been used as standard therapies for the treatment of chronic hepatitis B, and new drugs have been or are being developed to treat refractory mutant viral infections(*Cuestas et al., 2010*). Quantitative measures of HBsAg level in serum are important for monitoring response to anti-viral treatment during the management of patients with a chronic HBV infection(*Jung et al., 2010*).